Most companies' success stories come as a result of wanting to accomplish a greater purpose. For HAVN Life Sciences Inc. (CSE: HAVN) (OTC PINK: HAVLF) .
HealthTech Connex s Centre for Neurological Studies and the
NeuroCatch Platform (Surrey), the
Woodview Autism and Mental Health Services (Ontario). This partnership initiative emerged from Surrey s
Health and Technology District and is a product of decades of leading-edge research started by Dr. Catherine Mateer and Dr. Kimberly Kerns from the University of Victoria. It represents a major milestone in translating leading research into health technology benefits for Canadians and children around the globe.
Through a combination of research, clinical studies, innovation, and clinical expertise, the multi-year partnership enables collaborators to offer a video-game based treatment program for children with neurodevelopmental disabilities. Their goal is to help children with special needs reach their potential through the development and use of novel, evidence-based innovations, to improve neuro-behavioural outcomes in children with neurodevelopmental challenges.
5 Biotech Penny Stocks To Watch For March 2021 | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Boston Suburbs Look To Decriminalize Natural Psychedelics
That includes psilocybin mushrooms, ayahuasca, the peyote cacti and the iboga plant.
On Wednesday, Cambridge, Massachusetts voted 8 to 1 in its City Council to decriminalize “all Entheogenic Plants and plant-based compounds,” making them a lowest law enforcement priority (h/t Marijuana Moment).
Three weeks earlier, Somerville passed a similar measure with unanimous votes from its City Council.
Cambridge and Somerville have a population of over 105,000 and 80,000, respectively.
The Cambridge resolution makes notice of the fact that the so-called War on Drugs “has historically led to unnecessary penalization, arrest, and incarceration of vulnerable people, particularly people of color and of limited financial means.”
Havn Life Sciences Inc.: Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.
VANCOUVER, BC / ACCESSWIRE / February 2, 2021 / Havn Life Sciences Inc. (CSE:
HAVN
5NP
) (the Company or Havn Life ), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce a strategic partnership with neuroscience and technology leader, HealthTech Connex Inc.
Upon approval of the Company s Licensed Dealer application, the Company s subsidiary, Havn Labs, will be a preferred psychedelic supply partner for future clinical trials launched by HealthTech Connex s Centre for Neurology Studies. In addition, HealthTech Connex will promote Havn Life s library of naturally derived compounds to its other clinical trial partners and be a preferred partner for the execution of Havn Life clinical trials.